Compare ACHR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACHR | TMDX |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.6B |
| IPO Year | N/A | N/A |
| Metric | ACHR | TMDX |
|---|---|---|
| Price | $6.78 | $133.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $12.14 | ★ $144.25 |
| AVG Volume (30 Days) | ★ 36.2M | 720.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $38.73 |
| Revenue Next Year | N/A | $20.55 |
| P/E Ratio | ★ N/A | $52.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.48 | $62.07 |
| 52 Week High | $14.62 | $156.00 |
| Indicator | ACHR | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 49.52 |
| Support Level | $6.61 | $127.50 |
| Resistance Level | $7.57 | $140.72 |
| Average True Range (ATR) | 0.40 | 6.95 |
| MACD | -0.05 | -0.66 |
| Stochastic Oscillator | 22.45 | 35.01 |
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.